Clinical trial · no report yet · Phase 2
iTHYM
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
- NCT06750952 ↗
- Not yet recruiting
- Sun Yat-sen University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial (iTHYM)
- Phase
- Phase 2
- Status
- Not yet recruiting
- Conditions
- Relapsed or Metastatic Thymic Cancer; First-line Treatment
- Interventions
- Ivonescimab Combined With Chemotherapy
- Arms
- Ivonescimab · Experimental
- Enrollment
- 24 (estimated)
- Primary outcomes
- Progression free survival at 6 months（PFS 6m）
- Sponsor
- Sun Yat-sen University
- Start
- Dec 20, 2024 (estimated)
- Primary completion
- Dec 20, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06750952 · updated Dec 27, 2024